US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
DK0617612T3
(da)
|
1991-12-18 |
1998-04-14 |
Warner Lambert Co |
Fremgangsmåde til fremstilling af en fast dispersion
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5811547A
(en)
*
|
1992-10-14 |
1998-09-22 |
Nippon Shinyaju Co., Ltd. |
Method for inducing crystalline state transition in medicinal substance
|
KR950703326A
(ko)
*
|
1992-10-14 |
1995-09-20 |
아만 히데아키 |
결정상태의 전이방법
|
DE69332291T2
(de)
*
|
1992-10-16 |
2003-07-31 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung von wachsmatrizes
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP0717988B1
(de)
*
|
1993-08-20 |
2001-10-17 |
Nippon Shinyaku Company, Limited |
Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
|
GB2281697A
(en)
*
|
1993-09-14 |
1995-03-15 |
Euro Celtique Sa |
Laxative compositions in capsules
|
EP0729748B1
(de)
*
|
1993-11-18 |
2003-02-26 |
Nippon Shinyaku Company, Limited |
Verfahren zur herstellung stabiler arzneimittel
|
DE19509807A1
(de)
*
|
1995-03-21 |
1996-09-26 |
Basf Ag |
Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
ATE251896T1
(de)
*
|
1994-12-19 |
2003-11-15 |
Daiichi Seiyaku Co |
Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
WO1997004782A1
(fr)
*
|
1995-07-26 |
1997-02-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Dispersion solide ou preparation a dispersion solide de derives xanthine
|
TW487582B
(en)
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
NZ330739A
(en)
*
|
1996-05-20 |
1999-06-29 |
Janssen Pharmaceutica Nv |
Particulate solid dispersion of itraconazole and a water soluble polymer
|
US6139872A
(en)
*
|
1996-08-14 |
2000-10-31 |
Henkel Corporation |
Method of producing a vitamin product
|
JPH10114682A
(ja)
*
|
1996-10-11 |
1998-05-06 |
Shimizu Kagaku Kk |
グルコマンナン配合持効性内服用薬剤
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
DK0901786T3
(da)
|
1997-08-11 |
2007-10-08 |
Pfizer Prod Inc |
Faste farmaceutiske dispersioner med foröget biotilgængelighed
|
EP1741424B1
(de)
|
1997-08-11 |
2018-10-03 |
Pfizer Products Inc. |
Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
US6013280A
(en)
*
|
1997-10-07 |
2000-01-11 |
Fuisz Technologies Ltd. |
Immediate release dosage forms containing microspheres
|
AU8621398A
(en)
*
|
1998-01-12 |
1999-07-26 |
Buhler Ag |
Method and device for capsulating active ingredients
|
IE980115A1
(en)
*
|
1998-02-16 |
2000-02-09 |
Biovail Internat Ltd |
Solubilizing delivery systems and method of manufacture
|
KR100613706B1
(ko)
*
|
1998-05-27 |
2006-08-21 |
유로-셀띠끄 소시에떼 아노님 |
항염증용 제제, 특히 귀 및/또는 상부호흡기의 창상치료촉진용 약제 및/또는 소독 약제
|
DE19842914A1
(de)
*
|
1998-09-18 |
2000-03-23 |
Basf Ag |
Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
|
DE19842753A1
(de)
|
1998-09-18 |
2000-03-23 |
Bayer Ag |
Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
|
US6350786B1
(en)
†
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US6455526B1
(en)
|
1998-12-16 |
2002-09-24 |
Aventis Pharmaceuticals, Inc. |
Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
|
WO2000035423A1
(en)
*
|
1998-12-16 |
2000-06-22 |
Aventis Pharmaceuticals Inc. |
Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
|
ES2306646T3
(es)
*
|
1999-02-09 |
2008-11-16 |
Pfizer Products Inc. |
Composiciones de farmacos basicos con biodisponibilidad incrementada.
|
ES2307482T3
(es)
*
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
JP2000281561A
(ja)
*
|
1999-03-26 |
2000-10-10 |
Ajinomoto Co Inc |
新規溶媒法固体分散体製剤
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US7297344B1
(en)
|
1999-05-27 |
2007-11-20 |
Euro-Celtique, S.A. |
Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
|
AU772314B2
(en)
|
1999-05-27 |
2004-04-22 |
Euro-Celtique S.A. |
Preparations for the application of anti-inflammatory agents
|
US7300667B1
(en)
|
1999-05-27 |
2007-11-27 |
Euro-Celtique, S.A. |
Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
DE19949897A1
(de)
*
|
1999-10-15 |
2001-04-19 |
Rainer Rogasch |
Formkörper und Verfahren zu dessen Herstellung
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
NZ529928A
(en)
|
1999-10-29 |
2005-10-28 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
JP5767429B2
(ja)
|
1999-11-12 |
2015-08-19 |
アッヴィ・インコーポレイテッド |
固体分散剤中の結晶化阻害剤
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
JP2003518485A
(ja)
*
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
向上された薬物濃度を与える医薬組成物
|
CA2403380A1
(en)
*
|
2000-03-21 |
2002-09-19 |
Nippon Shinyaku Co., Ltd. |
Sustained release oral preparations
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
DE10031044A1
(de)
|
2000-06-26 |
2002-01-03 |
Bayer Ag |
Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
|
EP1302201A4
(de)
*
|
2000-07-17 |
2007-09-05 |
Astellas Pharma Inc |
Pharmazeutische zusammensetzung mit verbesserter peroraler absorbierbarkeit
|
US7115279B2
(en)
*
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
WO2002024168A1
(fr)
*
|
2000-09-25 |
2002-03-28 |
Nippon Shinyaku Co., Ltd. |
Procede de production d'une dispersion solide medicinale
|
KR101045144B1
(ko)
|
2000-10-30 |
2011-06-30 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
ITMI20010141A1
(it)
*
|
2001-01-26 |
2002-07-26 |
Giuliani Spa |
Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
|
CA2439366A1
(en)
*
|
2001-02-27 |
2002-09-06 |
Julie Cahill |
Pharmaceutical formulation comprising bicalutamide
|
GB0104752D0
(en)
*
|
2001-02-27 |
2001-04-18 |
Astrazeneca Ab |
Pharmaceutical compositions
|
US6465014B1
(en)
*
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
EP1401399A2
(de)
*
|
2001-06-22 |
2004-03-31 |
Pfizer Products Inc. |
Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
|
MXPA03011933A
(es)
|
2001-06-22 |
2004-03-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
|
JP2004534812A
(ja)
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
薬物および中性ポリマーの分散物の医薬組成物
|
EP1269994A3
(de)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
AU2002304387A1
(en)
*
|
2001-06-22 |
2003-01-08 |
Pfizer Products Inc. |
Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
SE0103424D0
(sv)
*
|
2001-10-15 |
2001-10-15 |
Astrazeneca Ab |
Pharmaceutical formulation
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
IL162870A0
(en)
|
2002-02-01 |
2005-11-20 |
Pfizer Prod Inc |
Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
|
AR038375A1
(es)
*
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
MXPA04007433A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
|
EP1920766B1
(de)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
|
US20030204180A1
(en)
*
|
2002-04-30 |
2003-10-30 |
Kimberly-Clark Worldwide, Inc. |
Temperature responsive delivery systems
|
DE60329188D1
(de)
|
2002-08-12 |
2009-10-22 |
Bend Res Inc |
Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
|
AU2003283769A1
(en)
|
2002-12-20 |
2004-07-14 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
US7423004B2
(en)
*
|
2003-01-31 |
2008-09-09 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
CA2509958A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Novartis Ag |
Pharmaceutical formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
KR20060096076A
(ko)
*
|
2003-11-14 |
2006-09-05 |
화이자 프로덕츠 인크. |
비만 치료를 위한 mtp 저해제의 고형 무정형 분산물
|
JP2007513937A
(ja)
*
|
2003-12-09 |
2007-05-31 |
ファイザー インコーポレイテッド |
Hivプロテアーゼ阻害剤を含む組成物
|
CA2555133A1
(en)
|
2004-02-04 |
2005-09-01 |
Pfizer Products Inc. |
Substituted quinoline compounds
|
US20050238721A1
(en)
*
|
2004-04-07 |
2005-10-27 |
Acquarulo Lawrence A Jr |
One step compounding extrusion of drug filled polymers
|
JP2007536299A
(ja)
*
|
2004-05-04 |
2007-12-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ltb4アンタゴニトを含有する固形医薬形態
|
CA2568056A1
(en)
|
2004-05-25 |
2005-12-08 |
Pfizer Products Inc. |
Tetraazabenzo[e]azulene derivatives and analogs thereof
|
MXPA06013891A
(es)
*
|
2004-05-28 |
2007-01-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas con comportamiento potenciado.
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
EP1848430B1
(de)
*
|
2004-12-31 |
2017-08-02 |
Dr. Reddy's Laboratories Ltd. |
Neue benzylaminderivate als cetp-inhibitoren
|
EP1844078B1
(de)
|
2005-02-03 |
2016-09-28 |
Bend Research, Inc |
Pharmazeutische zusammensetzungen mit erhöhter leistung
|
EP1690528A1
(de)
*
|
2005-02-11 |
2006-08-16 |
Abbott GmbH & Co. KG |
Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
|
BRPI0614197B8
(pt)
*
|
2005-08-02 |
2021-05-25 |
Drossapharm Ag |
composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
ES2713062T3
(es)
|
2005-09-27 |
2019-05-17 |
Tissuetech Inc |
Preparaciones de membrana amniótica y composiciones purificadas y métodos de uso
|
EA017290B1
(ru)
|
2005-11-28 |
2012-11-30 |
Домейн Раша Инвестментс Лимитед |
Композиции на основе ганаксолона
|
EP1832281A1
(de)
*
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes
|
US20080090897A1
(en)
|
2006-08-11 |
2008-04-17 |
The Johns Hopkins University |
Compositions and methods for neuroprotectin
|
EP2081435B1
(de)
|
2006-09-22 |
2016-05-04 |
Pharmacyclics LLC |
Hämmer der bruton-tyrosinkinase
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US7607596B1
(en)
|
2007-03-07 |
2009-10-27 |
Exxpharma, LLC |
Process for enhancing the solubility of poorly soluble drugs
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
US8974827B2
(en)
|
2007-06-04 |
2015-03-10 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
US9545384B2
(en)
|
2007-06-04 |
2017-01-17 |
Bend Research, Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
|
US20100190777A1
(en)
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
BRPI0814294A2
(pt)
*
|
2007-07-19 |
2015-02-03 |
Metabolex Inc |
Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
|
EP2187968A4
(de)
|
2007-08-21 |
2013-02-20 |
Univ Texas |
Thermokinetisches mischen für pharmazeutische anwendungen
|
CA2699157A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2009038112A1
(ja)
*
|
2007-09-21 |
2009-03-26 |
Shionogi & Co., Ltd. |
Npyy5受容体拮抗剤を含有する固形製剤
|
AU2008303129B2
(en)
*
|
2007-09-25 |
2013-08-01 |
Formulex Pharma Innovations Ltd. |
Compositions comprising lipophilic active compounds and method for their preparation
|
FR2922100B1
(fr)
*
|
2007-10-11 |
2009-12-11 |
Oreal |
Procede de preparation de particules semi-solides a interet cosmetique
|
WO2009053635A1
(fr)
*
|
2007-10-11 |
2009-04-30 |
L'oreal |
Composition cosmetique structuree
|
US9233078B2
(en)
|
2007-12-06 |
2016-01-12 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
|
WO2009073215A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
US20090163561A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
US20100048912A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
PL2280704T3
(pl)
*
|
2008-03-31 |
2015-10-30 |
Cymabay Therapeutics Inc |
Związki oksymetylenoarylowe i ich zastosowania
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
US20110312916A1
(en)
|
2009-02-05 |
2011-12-22 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
CR20170089A
(es)
|
2009-04-03 |
2017-07-17 |
Plexxikon Inc |
Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
|
ES2559029T3
(es)
|
2009-04-24 |
2016-02-10 |
Tissue Tech, Inc. |
Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
|
AU2010260208B2
(en)
|
2009-06-16 |
2014-11-13 |
Bristol-Myers Squibb Holdings Ireland Unlimited Company |
Dosage forms of apixaban
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
ES2497566T3
(es)
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
NZ599866A
(en)
|
2009-11-06 |
2014-09-26 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
JP5749790B2
(ja)
*
|
2010-03-26 |
2015-07-15 |
ダウ グローバル テクノロジーズ エルエルシー |
多層溶融押出フィルム
|
BR112012018818A2
(pt)
*
|
2010-03-26 |
2016-04-12 |
Dow Global Technologies Llc |
processo para produzir um filme extrudado de fundido e filme de extrudado de fundido
|
CN102892815B
(zh)
*
|
2010-03-26 |
2016-05-18 |
陶氏环球技术有限责任公司 |
熔体挤出的膜
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
WO2011153514A2
(en)
|
2010-06-03 |
2011-12-08 |
Pharmacyclics, Inc. |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
WO2011163090A1
(en)
|
2010-06-23 |
2011-12-29 |
Metabolex, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
CA2803377C
(en)
|
2010-07-02 |
2018-03-20 |
The Procter & Gamble Company |
Methods of delivering a health care active by administering personal health care articles comprising a filament
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
MA34948B1
(fr)
|
2011-02-07 |
2014-03-01 |
Plexxikon Inc |
Composes et procedes de modulation de kinase, et leurs indications
|
KR20140006879A
(ko)
|
2011-02-17 |
2014-01-16 |
에프. 호프만-라 로슈 아게 |
고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
DE102011015370A1
(de)
*
|
2011-03-29 |
2012-10-04 |
Emodys Gmbh |
Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
US9682044B2
(en)
|
2011-06-10 |
2017-06-20 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
MX2014001849A
(es)
|
2011-08-18 |
2014-10-24 |
Reddys Lab Ltd Dr |
Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
|
SG2014014419A
(en)
|
2011-09-13 |
2014-07-30 |
Pharmacyclics Inc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
CN103958511A
(zh)
|
2011-09-27 |
2014-07-30 |
雷迪博士实验室有限公司 |
作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
PT2800565T
(pt)
|
2012-01-06 |
2020-04-29 |
Scripps Research Inst |
Compostos de carbamato e processos para a sua preparação e utilização
|
IN2012DE00674A
(de)
|
2012-03-07 |
2015-08-21 |
Nat Inst Of Pharmaceutical Education And Res Niper |
|
MA37385B1
(fr)
|
2012-04-06 |
2019-09-30 |
Pfizer Inc Etat De Delaware |
Inhibiteurs de diacylglycérol-acyltransférase 2
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
NZ702548A
(en)
|
2012-06-04 |
2015-11-27 |
Pharmacyclics Llc |
Crystalline forms of a bruton’s tyrosine kinase inhibitor
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック,インク. |
Hc−ha/ptx3複合体を含む組成物およびその使用方法
|
EP2900674B1
(de)
|
2012-09-28 |
2017-05-31 |
University of Washington through its Center for Commercialization |
Verbindungen und verfahren zur vorbeugung, behandlung und/oder schutz vor haarzelltod
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
AU2013346501B2
(en)
|
2012-11-19 |
2017-07-13 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions of CETP inhibitors
|
JP6150518B2
(ja)
|
2012-12-27 |
2017-06-21 |
花王株式会社 |
ポリフェノール組成物の製造方法
|
WO2014128564A2
(en)
|
2013-02-21 |
2014-08-28 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions of cetp inhibitors
|
SG11201507093WA
(en)
|
2013-03-14 |
2015-10-29 |
Univ Maryland Baltimore Office Of Technology Transfer |
Androgen receptor down-regulating agents and uses thereof
|
RU2016104643A
(ru)
|
2013-08-12 |
2017-09-19 |
Токай Фармасьютикалз, Инк. |
Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
|
EP2837391B1
(de)
|
2013-08-12 |
2017-05-10 |
Shin-Etsu Chemical Co., Ltd. |
Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
|
US9296882B2
(en)
|
2013-09-04 |
2016-03-29 |
Zzyzx Polymers LLC |
Methods for increasing throughput rates of solid-state extrusion devices
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20150104508A1
(en)
*
|
2013-10-12 |
2015-04-16 |
Zzyzx Polymers LLC |
Devices, compositions, and methods for fabricating drug delivery systems
|
WO2015084998A1
(en)
|
2013-12-05 |
2015-06-11 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
SI3104853T1
(sl)
|
2014-02-10 |
2020-03-31 |
Respivant Sciences Gmbh |
Zdravljenje s stabilizatorji mastocitov za sistemske motnje
|
US20150224078A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers
|
AP2016009407A0
(en)
|
2014-03-17 |
2016-08-31 |
Pfizer |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
US10231929B2
(en)
|
2014-03-18 |
2019-03-19 |
Takeda Pharmaceutical Company Limited |
Solid dispersion
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
CN106793821B
(zh)
|
2014-08-29 |
2021-05-07 |
花王株式会社 |
含有难溶性多酚类的固体分散体的制造方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
WO2016044733A1
(en)
*
|
2014-09-19 |
2016-03-24 |
Board Of Regents, The University Of Texas System |
Methods of preparing extrudates
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
CN107438613B
(zh)
|
2015-02-06 |
2020-08-25 |
华盛顿大学 |
用于预防或治疗感觉毛细胞死亡的化合物和方法
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
BR122023020985A2
(pt)
|
2015-03-03 |
2023-12-26 |
Pharmacyclics Llc |
Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
CN113413387A
(zh)
|
2015-05-11 |
2021-09-21 |
H.隆德贝克有限公司 |
治疗炎症或神经性疼痛的方法
|
CN107847526A
(zh)
|
2015-05-20 |
2018-03-27 |
组织技术公司 |
用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
|
KR101994129B1
(ko)
|
2015-05-28 |
2019-06-28 |
닥터 레디스 레보러터리즈 리미티드 |
통증 치료를 위한 셀레콕시브 경구용 조성물
|
WO2017027402A1
(en)
|
2015-08-07 |
2017-02-16 |
Patara Pharma, LLC |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
EP3340982B1
(de)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Verbindungen zur behandlung von immun- und entzündungserkrankungen
|
BR112018003836A2
(pt)
|
2015-08-31 |
2018-12-04 |
Pharmacyclics Llc |
combinações de inibidor de btk para tratar mieloma múltiplo
|
US10975149B2
(en)
|
2015-12-16 |
2021-04-13 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced SH2 protein in NK cells
|
CN114681462A
(zh)
|
2016-01-19 |
2022-07-01 |
詹森药业有限公司 |
包含btk抑制剂的配制品/组合物
|
AU2017208472B2
(en)
|
2016-01-19 |
2022-09-01 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a BTK inhibitor
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
EP3442538A4
(de)
|
2016-04-04 |
2019-11-20 |
Sinopia Biosciences, Inc. |
Behandlung von extrapyramidalem syndrom mit trapidil
|
ES2910787T3
(es)
|
2016-05-12 |
2022-05-13 |
Univ Michigan Regents |
Inhibidores de ASH1L y métodos de tratamiento con los mismos
|
KR20210145306A
(ko)
|
2016-05-13 |
2021-12-01 |
메르크 파텐트 게엠베하 |
용융 압출 적용을 위한 중합체의 입자 크기 및 분포
|
KR102388870B1
(ko)
|
2016-05-13 |
2022-04-20 |
메르크 파텐트 게엠베하 |
가소제로서의 아미노 당의 용도
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
AU2017290593A1
(en)
|
2016-06-27 |
2019-01-03 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
JP2019524747A
(ja)
|
2016-07-18 |
2019-09-05 |
アースローシ セラピューティクス,インク. |
痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法
|
JP2019527693A
(ja)
|
2016-08-03 |
2019-10-03 |
サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. |
炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
JP7028860B2
(ja)
|
2016-08-26 |
2022-03-02 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
CA3035528A1
(en)
|
2016-08-31 |
2018-03-08 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
EP3522983A4
(de)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
Cromolynzusammensetzung zur behandlung von lungenfibrose
|
WO2018083285A1
(en)
|
2016-11-07 |
2018-05-11 |
Merck Patent Gmbh |
Controlled release tablet based on polyvinyl alcohol and its manufacturing
|
MX2019005304A
(es)
|
2016-11-07 |
2019-08-12 |
Merck Patent Gmbh |
Pastilla de liberacion no abrupta de una dosis inducida por alcohol basada en alcohol polivinilico.
|
KR20190083653A
(ko)
|
2016-11-07 |
2019-07-12 |
메르크 파텐트 게엠베하 |
고온 용융 압출된 폴리비닐 알코올에 기반하는 즉각 방출 캡슐
|
MA46867A
(fr)
|
2016-11-16 |
2019-09-25 |
Abide Therapeutics Inc |
Formulations pharmaceutiques
|
LT3541807T
(lt)
|
2016-11-16 |
2021-12-27 |
H. Lundbeck A/S |
Magl inhibitoriaus kristalinė forma
|
MX2019010756A
(es)
|
2017-03-10 |
2020-01-20 |
Pfizer |
Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
|
CN115093337A
(zh)
*
|
2017-08-01 |
2022-09-23 |
浙江普利药业有限公司 |
一种马来酸曲美布汀晶型及其制备方法
|
EP3675865A4
(de)
|
2017-09-01 |
2021-06-02 |
University of Washington |
Kristalline formen von verbindungen zur vorbeugung oder behandlung von sensorischem haarzelltod
|
WO2019094434A1
(en)
|
2017-11-07 |
2019-05-16 |
The Regents Of The University Of Michigan |
Therapeutic combination for treatment of cerebellar ataxia
|
WO2019094773A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
CN112040947A
(zh)
|
2017-12-07 |
2020-12-04 |
密歇根大学董事会 |
Nsd家族抑制剂及用其进行治疗的方法
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
US11319302B2
(en)
|
2018-06-07 |
2022-05-03 |
The Regents Of The University Of Michigan |
PRC1 inhibitors and methods of treatment therewith
|
WO2020023794A1
(en)
|
2018-07-27 |
2020-01-30 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic trpv1 agonists
|
JP2021535112A
(ja)
|
2018-08-20 |
2021-12-16 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
補体d因子の医学的障害の治療のための医薬化合物
|
US20200069742A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
MX2021002428A
(es)
|
2018-08-31 |
2023-01-02 |
Pfizer |
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
EP3866773A4
(de)
|
2018-10-16 |
2022-10-26 |
Georgia State University Research Foundation, Inc. |
Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
|
WO2020096660A1
(en)
|
2018-11-06 |
2020-05-14 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
MX2021007925A
(es)
|
2018-12-31 |
2021-10-26 |
Biomea Fusion Llc |
Inhibidores irreversibles de la interaccion menina-mll.
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
WO2020190890A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
WO2020210205A1
(en)
*
|
2019-04-08 |
2020-10-15 |
Cosci Med-Tech Co., Ltd |
Methods of improving pharmaceutical substance solubilization and products thereof
|
WO2020212865A1
(en)
|
2019-04-19 |
2020-10-22 |
Pfizer Inc. |
Anti-proliferative agents for treating pah
|
CA3140972A1
(en)
|
2019-05-20 |
2020-11-26 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
WO2020261144A1
(en)
|
2019-06-28 |
2020-12-30 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
CA3175210A1
(en)
|
2020-04-21 |
2021-10-28 |
Cheryl A. Grice |
Synthesis of a monoacylglycerol lipase inhibitor
|
CR20220632A
(es)
|
2020-06-09 |
2023-01-23 |
Pfizer |
Antagonistas del receptor de melanocortina 4 y usos de estos
|
CN116113406A
(zh)
|
2020-07-10 |
2023-05-12 |
密歇根大学董事会 |
Gas41抑制剂及其使用方法
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
WO2022238507A1
(en)
|
2021-05-11 |
2022-11-17 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
CA3221280A1
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
WO2024011142A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|